285 related articles for article (PubMed ID: 31721316)
21. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2.
Cork MJ; Eckert L; Simpson EL; Armstrong A; Barbarot S; Puig L; Girolomoni G; de Bruin-Weller M; Wollenberg A; Kataoka Y; Remitz A; Beissert S; Mastey V; Ardeleanu M; Chen Z; Gadkari A; Chao J
J Dermatolog Treat; 2020 Sep; 31(6):606-614. PubMed ID: 31179791
[No Abstract] [Full Text] [Related]
22. Do Atopic Dermatitis Patient-Reported Outcomes Correlate With Validated Investigator Global Assessment? Insights From TARGET-AD Registry.
Guttman-Yassky E; Bar J; Rothenberg-Lausell C; Eichenfield L; Grada A; Abuabara K; Chapman M; Calimlim B; Wegzyn C; Gamelli A; Krueger W; Munoz B; Knapp K; Faller R; Crawford J; Silverberg J
J Drugs Dermatol; 2023 Apr; 22(4):344-354. PubMed ID: 37026893
[TBL] [Abstract][Full Text] [Related]
23. Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials.
Griffiths C; de Bruin-Weller M; Deleuran M; Fargnoli MC; Staumont-Sallé D; Hong CH; Sánchez-Carazo J; Foley P; Seo SJ; Msihid J; Chen Z; Cyr SL; Rossi AB
Dermatol Ther (Heidelb); 2021 Aug; 11(4):1357-1372. PubMed ID: 34142350
[TBL] [Abstract][Full Text] [Related]
24. What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational study.
Silverberg JI; Lei D; Yousaf M; Janmohamed SR; Vakharia PP; Chopra R; Chavda R; Gabriel S; Patel KR; Singam V; Kantor R; Hsu DY
Br J Dermatol; 2021 May; 184(5):888-895. PubMed ID: 32959390
[TBL] [Abstract][Full Text] [Related]
25. Treatment outcomes of patients with Atopic Dermatitis (AD) treated with dupilumab through the Early Access to Medicines Scheme (EAMS) in the UK.
O'Kane D; Davis L; Ardern-Jones M; Laws P; Shaw L; Cork M; Velangi S; Cooper HL; Hudson R; Smith AB; Rout R
Ulster Med J; 2021 May; 90(2):70-76. PubMed ID: 34276083
[TBL] [Abstract][Full Text] [Related]
26. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
[TBL] [Abstract][Full Text] [Related]
27. Atopic Dermatitis in Children in the General Population: Baseline Characteristics, Medication Use, and Severity Measures in the Rotterdam Eczema Study.
van Halewijn KF; van der Most F; Bohnen AM; Pasmans SGMA; Bindels PJE; Elshout G
Dermatitis; 2024; 35(1):61-69. PubMed ID: 37015063
[No Abstract] [Full Text] [Related]
28. Validation of patient-reported global severity of atopic dermatitis in adults.
Vakharia PP; Chopra R; Sacotte R; Patel N; Immaneni S; White T; Kantor R; Hsu DY; Silverberg JI
Allergy; 2018 Feb; 73(2):451-458. PubMed ID: 28905999
[TBL] [Abstract][Full Text] [Related]
29. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis.
Chopra R; Vakharia PP; Sacotte R; Patel N; Immaneni S; White T; Kantor R; Hsu DY; Silverberg JI
Br J Dermatol; 2017 Nov; 177(5):1316-1321. PubMed ID: 28485036
[TBL] [Abstract][Full Text] [Related]
30. Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study.
Napolitano M; Fabbrocini G; Neri I; Stingeni L; Boccaletti V; Piccolo V; Amoruso GF; Malara G; De Pasquale R; Di Brizzi EV; Diluvio L; Bianchi L; Chiricozzi A; Di Guida A; Del Duca E; Moschese V; Di Lernia V; Dragoni F; Gruber M; Hansel K; Licari A; Manti S; Leonardi S; Mastorino L; Ortoncelli M; Provenzano E; Palermo A; Patella V; Peduto T; Pezzolo E; Piras V; Potestio L; Battista T; Satta R; Termine S; Palma P; Zangari P; Patruno C
Paediatr Drugs; 2022 Nov; 24(6):671-678. PubMed ID: 36028611
[TBL] [Abstract][Full Text] [Related]
31. Longitudinal course and phenotypes of health-related quality of life in adults with atopic dermatitis.
Schwartzman G; Lei D; Ahmed A; Chavda R; Gabriel S; Silverberg JI
Clin Exp Dermatol; 2022 Feb; 47(2):359-372. PubMed ID: 34623642
[TBL] [Abstract][Full Text] [Related]
32. Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis.
Yosipovitch G; de Bruin-Weller M; Armstrong A; Wu JJ; Herranz P; Thaçi D; Delevry D; Bagousse GB; Zhang R; Shumel B; Rossi AB; Chao J
Dermatol Ther (Heidelb); 2021 Dec; 11(6):2147-2157. PubMed ID: 34714527
[TBL] [Abstract][Full Text] [Related]
33. Exploring the Relationship Between Dermatology Life Quality Index, Eczema Area and Severity Index, and Sleep Numerical Rating Scale and Pruritus Numerical Rating Scale in Patients with Atopic Dermatitis Treated with Dupilumab.
Russo F; Cioppa V; Cartocci A; De Piano E; Taddeucci P; Lazzeri L; Santi F; Rubegni P
Dermatitis; 2023; 34(5):440-444. PubMed ID: 36917539
[No Abstract] [Full Text] [Related]
34. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation.
Schmitt J; Langan S; Deckert S; Svensson A; von Kobyletzki L; Thomas K; Spuls P;
J Allergy Clin Immunol; 2013 Dec; 132(6):1337-47. PubMed ID: 24035157
[TBL] [Abstract][Full Text] [Related]
35. Systemic Immunomodulatory Treatments for Atopic Dermatitis: Update of a Living Systematic Review and Network Meta-analysis.
Drucker AM; Morra DE; Prieto-Merino D; Ellis AG; Yiu ZZN; Rochwerg B; Di Giorgio S; Arents BWM; Burton T; Spuls PI; Schmitt J; Flohr C
JAMA Dermatol; 2022 May; 158(5):523-532. PubMed ID: 35293977
[TBL] [Abstract][Full Text] [Related]
36. Establishment and Utility of SwedAD: A Nationwide Swedish Registry for Patients with Atopic Dermatitis Receiving Systemic Pharmacotherapy.
Alsterholm M; Svedbom A; Anderson CD; Holm Sommar L; Ivert LU; Josefson A; Von Kobyletzki L; Lindberg M; Lundeberg L; Lundqvist M; Nylander E; Sandström Falk M; Shayesteh A; Sigurdardottir G; Sonesson A; Svensson Å; Virtanen M; Vrang S; Wahlgren CF; Bradley M; Johansson EK
Acta Derm Venereol; 2023 Apr; 103():adv7312. PubMed ID: 37021597
[TBL] [Abstract][Full Text] [Related]
37. Severity strata for POEM, PO-SCORAD, and DLQI in US adults with atopic dermatitis.
Silverberg JI; Gelfand JM; Margolis DJ; Fonacier L; Boguniewicz M; Schwartz LB; Simpson E; Grayson MH; Ong PY; Fuxench ZCC
Ann Allergy Asthma Immunol; 2018 Oct; 121(4):464-468.e3. PubMed ID: 30003968
[TBL] [Abstract][Full Text] [Related]
38. Real-World Clinical Experience of Dupilumab in the Treatment of Chronic Palmo-Plantar Eczema in Patients with Moderate-Severe Atopic Dermatitis: 52-Week Follow-Up.
Navarro-Triviño FJ; Galán-Gutiérrez M; Hita JC; Ruiz-Villaverde R; Domínguez-Cruz J; Pereyra-Rodríguez JJ
Dermatitis; 2024; 35(S1):S55-S61. PubMed ID: 37883648
[No Abstract] [Full Text] [Related]
39. Effectiveness and safety of dupilumab in adults with moderate and severe atopic dermatitis in Colombia: Real-life experience.
Londoño J; Perez L; Moreno S; Chapman E; Garcia MB; Celis AM; Muñoz MA; Castillo D; Sánchez J; Arevalo Y; Lozano A; Alvis-Zakzuk NJ; Muñoz C; Botero L; Beltran C; García E
World Allergy Organ J; 2023 Apr; 16(4):100763. PubMed ID: 37091550
[TBL] [Abstract][Full Text] [Related]
40. Associations Between Shower and Moisturizing Practices with Atopic Dermatitis Severity: A Prospective Longitudinal Cohort Study.
Rakita U; Kaundinya T; Silverberg JI
Dermatitis; 2023; 34(5):425-431. PubMed ID: 36917546
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
